Microdosing of LSD does not show efficacy in adults with ADHD
The Brown University Psychopharmacology Update July 1, 2025 DOI: 10.1002/pu.31324 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Phase 2A trial Peer reviewed |
|---|---|
| Population | Adults with attention-deficit hyperactivity disorder (ADHD) |
| Intervention | LSD |
| Duration | 6-week intervention |
| Topics | LSD Microdosing |
| Key findings | Microdosing LSD over six weeks showed no significant benefits over placebo in reducing ADHD symptoms in adults. |
Abstract
Microdosing of lysergic acid diethylamide (LSD) over a 6‐week period showed no significant benefits over placebo in reducing symptoms of attention‐deficit hyperactivity disorder (ADHD) in adults, a Phase 2A trial has found. Both the LSD and placebo groups experienced marked improvement, the investigators reported.